[Federal Register Volume 61, Number 29 (Monday, February 12, 1996)]
[Notices]
[Pages 5404-5405]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-3073]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting Robert Benson, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 
(telephone 301/496-7056 ext. 267; fax 301/402-0220). A signed 
Confidential Disclosure Agreement will be required to receive copies of 
the patent applications.

Attenuated Human Rotavirus Vaccine

Hoshino, Y., Kapikian, A.Z., and Chanock, R.M. (NIAID)
Filed 11 July 95 (priority to 11 Jul 94)
    Serial No. 08/500,564 (CIP of 08/481,644)

    Rotaviruses are recognized as the single most important etiologic 
agent of severe diarrhea in both developed and nondeveloped countries. 
This invention embodies an attenuated rotavirus as a vaccine. The 
claims of the invention relate to the generation of a cold-adapted 
virus that is not efficient in replication at normal human body 
temperatures and therefore may be capable of stimulating an immune 
response without causing illness. In a limited clinical trial, 
administration of a cold-adapted rotavirus vaccine to 26 adults 
demonstrated that the vaccine was safe, attenuated, and was capable of 
inducing a virus-specific serologic response. This invention has been 
PCT filed on July 11, 1995. (portfolio: Infectious Diseases--Vaccines, 
viral, non-AIDS)

Method for Generating Influenza A Viruses Bearing Attenuating 
Mutations in Internal Protein Genes

Murphy, B., Subbarao, K.E., Kawaoka, Y. (NIAID)
Filed 7 Jun 95
Serial No. 08/481,631 (CIP of 08/309,521, CIP of 08/123,933)

    This invention describes a method of producing attenuated Influenza 
A strains for use as live Influenza A virus vaccine candidates. This 
method involves the introduction of three temperature-sensitive 
attenuating mutations into the polymerase basic protein 2 (PB2) gene of 
Influenza A virus. These mutations are introduced by site-directed 
mutagenesis at specific sites into a cDNA copy of the PB2 gene. An RNA 
transcript of this nutant PB2 gene is recovered into an infectious 
Influenza A virus using a host range restricted helper virus. This 
attending mutant PB2 gene can be transferred to each new variant of 
Influenza A virus as it appears in nature. The patent application 
covering this invention is available for licensing and contains claims 
to: The methods of producing the attenuated strains; the attenuated 
strains produced by the methods; and methods of vaccination using the 
attenuated strains. Viruses containing mutant PB2 genes are also 
available for licensing. (portfolio: Infectious Diseases--Vaccines, 
viral, non-AIDS)

Attenuated Influenza A Virus

Palese, P., Muster, T., Murphy, B.R., Enami, M., Bergmann, M., Subbaro, 
E.K., Chanock, R.M. (NIAID)
Filed 7 Jun 95 (priority to 3 Feb 92)
Serial No. 08/480,939 (FWC of 07/939,716)

    This invention describes the development of a novel live attenuated 
influenza A virus for use in intranasal vaccines. This virus is unique 
in that it is a chimera of two influenza strains. This results in an 
attenuated virus capable of invoking an immune response and therefore 
protection against influenza. The claims of this invention cover a 
method for generating the attenuated influenza virus, introducing the 
viral construct into cell lines, and vaccinating a vertebrate with the 
attenated virus. Animal studies have demonstrated that infection with 
the chimeric virus leads to resistance to a challenge with wild-type 
virus. (portfolio: Infectious Diseases--Vaccines, viral, non-AIDS)

Pteridine Nucleotide Analogs as Fluorescent DNA Probes

Hawkins, M.E., Pfleiderer, W., Davis, M.D., Balis, F.M. (NCI)

[[Page 5405]]

Filed 26 May 95
Serial No. 08/451,641 (DIV of 08/245,923)

    The invention concerns a series of pteridine deoxyribonucleotide 
analogs which are highly fluorescent and resemble purine nucleotides in 
chemical structure and properties. The phosphoramidite form of these 
fluorophores can be site-specifically incorporated into 
oligonucleotides using conventional DNA synthesis techniques. The 
fluorescence intensity of the pteridine nucleotide analogs is highly 
dependent on their physicochemical environment, thus making them ideal 
for the study of DNA-protein interactions. A real-time assay for HIV 
integrase has been developed using one of the pteridine nucleotide 
analogs that resembles guanosine. Other uses foreseen are as 
fluorescent labels for DNA probes and PCR primers and for investigating 
protein-DNA interactions. The claims include the phosphoramidite 
derivatives of the pteridine nucleotide analogs useful as starting 
materials for oligonucleotide synthesis and oligonucleotides 
incorporating the pteridine nucleotide analogs. (portfolio: Gene-Based 
Therapies--Research Tools and Reagents; Gene-Based Therapies--
Diagnostics)

    Dated: February 1, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-3073 Filed 2-9-96; 8:45 am]
BILLING CODE 4140-01-M